Showing 1 - 6 results of 6 for search 'V. M. Tolmachev', query time: 0.01s Refine Results
  1. 1
    Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins

    Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins by O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev

    Published 2022-10-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Possibilities of predicting the HER2 / neu status in a primary tumor in breast cancer patients using <sup>99m</sup>Tc-DARPinG3

    Possibilities of predicting the HER2 / neu status in a primary tumor in breast cancer patients using <sup>99m</sup>Tc-DARPinG3 by O. D. Bragina, L. A. Tashireva, V. I. Chernov, S. M. Deyev, V. M. Tolmachev

    Published 2023-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    A direct comparison of the diagnostic efficacy of alternative scaffoldbased radiopharmaceuticals [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 in patients with HER2-positive breast cancer

    A direct comparison of the diagnostic efficacy of alternative scaffoldbased radiopharmaceuticals [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 in patient... by O. D. Bragina, S. M. Deyev, E. Yu. Garbukov, V. E. Goldberg, V. I. Chernov, V. M. Tolmachev

    Published 2023-10-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer

    Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer by O. D. Bragina, V. I. Chernov, E. Yu. Garbukov, R. V. Zelchan, A. A. Medvedeva, V. M. Tolmachev

    Published 2021-06-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use

    Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use by O. D. Bragina, V. I. Chernov, E. Yu. Garbukov, A. V. Doroshenko, A. G. Vorobyeva, A. M. Orlova, V. M. Tolmachev

    Published 2021-04-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)

    EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT) by O. D. Bragina, V. I. Chernov, R. V. Zelchan, A. A. Medvedeva, I. G. Frolova, E. A. Dudnikova, V. E. Goldberg, V. M. Tolmachev

    Published 2021-10-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: